Faro Health

Faro Health is a San Diego, California-based software company that develops artificial intelligence-powered platforms to streamline clinical trial protocol design and drug development. The enterprise software-as-a-service platform replaces traditional static documents with digitized, data-driven collaborative workflows that integrate directly with existing clinical trial technologies. By automating complex processes, the system assists biotechnology, pharmaceutical, and life sciences organizations in reducing operational costs, improving patient experiences, and shortening overall research timelines. The company recently secured $20 million in additional venture capital financing led by the investment firm General Catalyst, alongside strategic connections to prominent industry players like Versant Ventures. Furthermore, the firm's technological framework has been highlighted across various industry media platforms, including executive appearances on The Uprising Show and the Master Move podcast. Faro Health was founded in 2019 by Scott Chetham and Ross Jaffe.

High-Level Overview

Faro Health is a healthcare software company building an AI-powered platform that accelerates clinical trial design and execution for biopharma teams. It serves pharmaceutical companies, biotech firms, CROs (Contract Research Organizations), research sites, vendors, patients, and labs by solving inefficiencies in protocol development—replacing manual processes like MS Word drafting with real-time insights, predictive analytics, and automation to create patient-centric, cost-effective trials.[1][2][3][4][5] The platform optimizes study protocols, generates drafts in minutes, automates workflows like EDC (Electronic Data Capture) builds, and has demonstrated proven ROI, including over $300M in potential cost savings, 200K patient hours avoided, and 1500+ RVUs (Relative Value Units) avoided across users.[3]

Launched as a cloud-based solution, Faro integrates prior study data to reduce patient attrition, streamline budgeting, and enable faster study startups, with top drug developers already using it to cut trial time and costs while scaling to complex, decentralized trials.[1][2][4]

Origin Story

Faro Health launched in 2019 as a cloud-computing company headquartered in San Diego, California, focused on digital infrastructure for clinical trials.[4][5] While specific founders are not detailed in available sources, the company emerged to address siloed, static data in drug development, where protocols are traditionally drafted in outdated tools like MS Word and emailed for feedback, limiting learning from past studies.[1] Early traction came from its proprietary platform's ability to connect stakeholders—including sponsors, CRO ClinOps teams, sites, vendors, patients, and labs—via a standardized library of study activities augmented with real-world performance data.[4][5]

Pivotal moments include securing a $20M financing round led by General Catalyst, announced around 2023-2024, to scale its Protocol Designer tool, and joining Microsoft for Startups to leverage Azure for global growth, enhanced security, and developer tools.[1][4] By 2025, Faro evolved its brand and AI capabilities, as seen in insights on agentic AI for drug development and FDA data practices.[3]

Core Differentiators

• AI-Powered Protocol Design: Real-time insights from prior studies predict patient attrition, budgeting impacts, and timeline trade-offs, enabling patient-centric iterations that reduce amendments and complexity.[1][2][3]
• End-to-End Workflow Automation: Generates high-quality drafts in minutes, automates EDC builds, and orchestrates downstream processes for faster study startup and operational alignment.[2][3][4]
• Seamless Integration and Scalability: Connects with existing clinical tech stacks, uses structured knowledge from real-world data, and supports unique trials with visualizations of patient journeys for inclusive, decentralized designs.[1][2][4]
• Stakeholder Collaboration: Single platform uniting sponsors, CROs, sites, vendors, patients, and labs with intuitive tools, reducing manual effort and ensuring transparency.[4][5]
• Proven, Measurable Impact: Trusted by industry leaders with quantified outcomes like $300M+ cost savings and partnerships like Microsoft for Startups.[3][4]

Role in the Broader Tech Landscape

Faro Health rides the wave of AI-driven digital transformation in clinical trials, addressing a core industry pain point: inefficient protocol design amid rising drug development costs and demands for faster, patient-focused studies.[1][2][3] Timing is ideal as biopharma shifts to decentralized trials, real-world evidence, and agentic AI—evidenced by Faro's 2025 content on FDA AI ambitions and evolved platforms—while market forces like regulatory pressures for efficiency and post-pandemic data silos favor digital-native tools.[1][3][4]

By distilling siloed data into actionable insights, Faro influences the ecosystem as an indispensable infrastructure layer, empowering teams to accelerate novel medicines, cut burdens on patients/clinicians, and enable downstream automation, much like General Catalyst envisions for tech-enabled trials.[1][6]

Quick Take & Future Outlook

Faro Health is poised for rapid scaling, building on its $20M raise, Microsoft partnership, and AI advancements to capture more biopharma market share amid exploding demand for efficient trials.[1][3][4] Trends like agentic AI, better FDA data practices, and decentralized studies will propel its intelligent engine, potentially expanding to full trial execution and global enterprise adoption. Its influence could evolve from protocol optimizer to ecosystem orchestrator, further reducing costs and speeding therapies—cementing its role in smarter clinical development, as it powers the digital trials future from day one.[1][2][3]